Patients must NOT have an active severe infection defined as:\r\n* A positive blood culture within  hours of study enrollment\r\n* A fever above . celsius (C) AND clinical signs of infection within  hours of study enrollment
RETREATMENT WITH MODIFIED T-CELLS EXCLUSION CRITERIA: Patients has an active severe infection defined as:\r\n* A positive blood culture within  hours of scheduled T cell infusion OR\r\n* A fever above . C AND clinical signs of infection within  hours of T cell infusion
Patients should have body Temperature <= . degrees C.
Patients with active infection or with a fever > . degrees (^) Celsius (C) within three days prior to the first treatment
Research participant does not have a fever exceeding . degrees Celsius (C); there is an absence of positive blood cultures for bacteria, fungus, or virus within -hours prior to T cell infusion and/or there arent any indications of meningitis
Subjects must NOT have an active severe infection defined as:\r\n* A positive blood culture within  hours of study enrollment\r\n* A fever above . Celsius (C) AND clinical signs of infection within  hours of study enrollment
Any infection requiring parenteral antibiotic therapy or causing fever (temperature > . degrees Fahrenheit [F] or . degrees Celsius [C]) within  week prior to registration
Active infection requiring treatment or an unexplained febrile (> . degrees Fahrenheit [F]) illness
Patients with an active infection requiring intravenous treatment or having an unexplained febrile illness (time to maximum concentration [Tmax] > . degrees Fahrenheit [F], . degrees Celsius [C])
Subjects must NOT have an active severe infection defined as:\r\n* A positive blood culture within  hours of study enrollment\r\n* A fever above . Celsius (C) AND clinical signs of infection within  hours of study enrollment
Patients with an active infection requiring intravenous treatment or having an unexplained febrile illness (maximum temperature [Tmax] > . degrees Fahrenheit [F])
Patients with severe, active co-morbidity, defined as follow:\r\n* Patients with an active infection requiring intravenous treatment or having an unexplained febrile illness (maximum temperature [Tmax] > . degrees Fahrenheit [F]/. degrees Celsius [C])\r\n* Patients with known immunosuppressive disease or known human immunodeficiency virus infection\r\n* Patients with unstable or severe intercurrent medical conditions such as severe heart disease (New York Heart Association class  or )\r\n* Patients with known lung (forced expiratory volume in  second [FEV] < %) disease or uncontrolled diabetes mellitus\r\n* Patients with albumin allergy\r\n* Patients with gadolinium allergy
Subjects with active infection or with a fever > . degrees Celsius (C) within t days prior to the first scheduled treatment
Active infection requiring intravenous antibiotics or an unexplained febrile (> . degrees Fahrenheit [F]) illness
Registered patients with an active infection or with a fever of ? . Celsius degrees (C) within  hours of the first scheduled day of protocol initiation will be excluded until their infection and/or fever resolves
Documented infections or oral temperature > . degree Celsius (C) fewer than  hours prior to receiving study treatment or systemic infection requiring chronic maintenance therapy; however, if these problems resolve, the start of treatment can be initiated on a delayed schedule
Active infection requiring treatment or an unexplained febrile (> . degrees Fahrenheit [F]) illness
Known active infections or oral temperature > . Celsius (C) fewer than  hours prior to receiving study treatment or systemic infection requiring chronic maintenance or suppressive therapy
Active infection requiring treatment or an unexplained febrile (> . degrees Fahrenheit [F]) illness
Patients with uncontrolled active infections (fever >=  degrees Celsius [C], septic shock)
Patient must NOT have an active severe infection defined as:\r\n* A positive blood culture within  hours of study enrollment\r\n* A fever above . Celsius (C) AND clinical signs of infection within  hours of study enrollment
ELIGIBILITY CRITERIA FOR T-CELL PRODUCT INFUSION: Patients must NOT have an active severe infection defined as:\r\n* A positive blood culture within  hours of scheduled T cell infusion\r\n* A fever above . C AND clinical signs of infection within  hours of T cell infusion
RETREATMENT WITH MODIFIED T CELLS: Patient has an active severe infection defined as:\r\n* A positive blood culture within  hours of scheduled T cell infusion\r\n* A fever above . C AND clinical signs of infection within  hours of T cell infusion
Patients with core body temperature >  degrees Celsius (C) at completion of cytoreductive surgery and prior to HIPEC
Patients with neutropenic fever who have existing malignancy or have undergone hematopoietic stem cell transplantation; neutropenic fever is defined as the presence of neutropenia defined by: ) absolute neutrophil count (ANC) <  cells/mm^ or has an ANC that is expected to decrease to <  cells/mm^ within  hours of trial entry and fever defined as: ) single oral temperature measurement of >  degree Fahrenheit (F) (. degree Celsius [C]) or a temperature of > . degree F (. degree C) sustained over a -hour period
Patients with active infections or oral temperature > . Celsius (C) within  hours of leukapheresis. The procedure may be deferred.
Active infection =<  days prior to registration or fever >  degrees Celsius (C) on day of registration
Active infection: temperature >  Fahrenheit (F), fever of unknown origin, active symptoms or signs of infection as defined by the investigator
Active infections or oral temperature > . Celsius (C) within  hours of study entry
Any infection requiring parenteral antibiotic therapy or causing fever (temperature > . degrees Fahrenheit [F] or . degrees Celsius [C]) within  week prior to registration
Patients with an active infection or with a fever >= . degrees Fahrenheit (F) within  days of the first scheduled day of protocol treatment
Uncontrolled infection, fever >  degrees F; or antibiotic therapy <  hours prior to registration; or urinary tract infection <  hours prior to registration
Active infection requiring systemic antibiotic therapy or causing fever (temp > . degrees Fahrenheit [F] or . degrees Celsius [C]) within  week prior to dosing with AZD
Patient has active infection at time of study entry that require systemic antibiotics and/or with an oral temperature of >= . degrees C (. degrees Fahrenheit [F]) within  days of first treatment
Documented infections or known oral temperature > . degrees Celsius (C) fewer than  hours prior to receiving study treatment or systemic infection requiring chronic maintenance; the start of treatment may be delayed
Active infection =<  days prior to registration or fever >  degrees Celsius (C) on day of registration
Active infection or unexplained fever > . degrees Celsius (C) (> . degrees Fahrenheit [F]) within  weeks prior to enrollment
Participant has an active infection or unexplained fever > . degrees Celsius (C) (. degrees Fahrenheit [F])
Patients with an active infection requiring treatment or an unexplained febrile (> . degrees Fahrenheit [F]) illness
Patients with active infection or with a fever > . degrees Celsius (C) within three days prior to the first scheduled treatment
Temperature =<  Celsius (C) (=< . Fahrenheit [F])
The subject has active infection or fever > . degrees Celsius (C) within  days prior to first dose of study drug
Temperature =<  Celsius (C) (=< . Fahrenheit [F])
Normal body temperature (=<  degrees F)
Presence of fever (>=  degrees F)
Fever of >  degrees Fahrenheit (F) or blood pressure (BP) > /
Fever (>  Celsius [C]), chills or rigor
